Skip to main content

Advertisement

SpringerLink
Log in

Is there a consensus between clinical practice guidelines for conventional and molecular nuclear medicine studies in parathyroid pathology?

  • Review Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Hyperparathyroidism is a common calcium metabolic disorder, characterized by the presence of high concentrations or inappropriately normal concentrations of parathyroid hormone (PTH) in the context of high calcium. Pharmacological and surgical management is available as treatment. The objective of diagnostic imaging is to determine the location of the causal lesion. For these purposes, non-invasive methods can be divided into anatomical or functional studies, with nuclear medicine studies being in the latter category. The objective of this review, is to establish the similarities and differences that exist in the clinical practice guidelines on conventional and molecular nuclear medicine studies in parathyroid disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bilezikian JP, Bandeira L, Khan A, Cusano NE. Hyperparathyroidism. Lancet. 2018;391(10116):168–78. https://doi.org/10.1016/S0140-6736(17)31430-7.

    Article  CAS  PubMed  Google Scholar 

  2. Yuen NK, Ananthakrishnan S, Campbell MJ. Hyperparathyroidism of renal disease. Perm J Summer. 2016;20(3):15–127. https://doi.org/10.7812/TPP/15-127.

    Article  Google Scholar 

  3. Wojtczak B, Syrycka J, Kaliszewski K, Rudnicki J, Bolanowski M, Barczyński M. Surgical implications of recent modalities for parathyroid imaging. Gland Surg. 2020;9(Suppl 2):S86–94. https://doi.org/10.21037/gs.2019.11.10.

    Article  PubMed  PubMed Central  Google Scholar 

  4. National center for complementary and integrative health (2021). Clinical practice guidelines. Available in: https://www.nccih.nih.gov/health/providers/clinicalpractice. Accessed 4 Apr 2021.

  5. ACR–SPR. Practice parameter for the performance of parathyroid scintigraphy (2019). Resolution 38. Available in: https://www.acr.org/-/media/ACR/Files/Practice-Parameters/parathyroidscint.pdf. Accessed 4 Apr 2021.

  6. Redman S, Graham R, Little D (2019) British nuclear medicine society clinical guideline for parathyroid scintigraphy version 1. Available in: https://cdn.ymaws.com/www.bnms.org.uk/resource/resmgr/guidelines/parathyroid_scintigraphy_fin.pdf. Accessed 4 Apr 2021.

  7. Ovčariček PP, Giovanella L, Gasset IC, Hindié E, Huellner MW, Luster M, et al. The EANM practice guidelines for parathyroid imaging. Eur J Nucl Med Mol Imaging. 2021. https://doi.org/10.1007/s00259-021-05334-y.

    Article  Google Scholar 

  8. Oxford centre for evidence-based medicine. Levels of evidence (2009) March. Available in: https://www.cebm.ox.ac.uk/resources/levels-of-evidence/oxford-centre-for-evidence-based-medicine-levels-of-evidence-march-2009. Accessed 4 Apr 2021.

  9. Damien M, Rodriguez A, Kleynen P, Dequanter D, Bouland C. An unusual case of primary hyperparathyroidism: case report of a bifocal intrathyroidal parathyroid carcinoma. Ear Nose Throat J. 2020. https://doi.org/10.1177/0145561320977466.

    Article  PubMed  Google Scholar 

  10. Fernando PEA, Bautista PA. Utility of 99mTc-sestamibi SPECT/CT in the early localization of metastatic parathyroid carcinoma. Asia Ocean J Nucl Med Biol. 2018;6(2):171–8. https://doi.org/10.22038/aojnmb.2017.27484.1190.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Acuña Hernández M, Morales T, González A, Sarmiento J (2018) Carcinoma de paratiroides: hallazgo en gammagrafía con 99mTc- Sestamibi. Alasbimn Journal. Available in: http://www.alasbimnjournal.net/contenidos/carcinoma-de-paratiroides-hallazgo-en-gammagrafia-con-99mtc-sestamibi-184. Accessed 18 Apr 2021.

  12. Kitapçi M, Tastekin G, Turgut M, Caner B, Kars A, Barista I, et al. Preoperative localization of parathyroid carcinoma using 99mTc-MIBI. Clin Nucl Med. 1993;18(3):217–9. https://doi.org/10.1097/00003072-199303000-00007.

    Article  PubMed  Google Scholar 

  13. Singhal T, Jacobs M, Mantil JC. 99mTc-pertechnetate/sestamibi subtraction scan in a case of parathyroidcarcinoma. Clin Nucl Med. 2008;33(3):196–7. https://doi.org/10.1097/RLU.0b013e318162dd4d.

    Article  PubMed  Google Scholar 

  14. Campennì A, Ruggeri RM, Sindoni A, Giovinazzo S, Calbo L, Leni A, et al. Parathyroid carcinoma as a challenging diagnosis: report of three cases. Hormones (Athens). 2012;11(3):368–76. https://doi.org/10.14310/horm.2002.1367.

    Article  Google Scholar 

  15. Salsidua-Arroyo O, Jiménez-Ballvé A, Lapeña Gutiérrez L, Riola-Parada C, Ochagavia Cámara S, Carreras-Delgado JL (2015) Gammagrafía con Tc-sestaMIBI en hiperparatiroidismo con diagnóstico histológico de carcinoma de paratiroides. Alasbimn Journal. Available in: http://www.alasbimnjournal.net/contenidos/gammagrafia-con-sup-99m-sup-tc-sestamibi-en-hiperparatiroidismo-con-diagnostico-histologico-de-carcinoma-de-paratiroides-145. Accessed 18 Apr 2021.

  16. Nevena R, Sinisa S, Daniela PG, Meri A. Scintigraphic evaluation of multifocal osteolytic lesions in a patient with primary hyperparathyroidism: a case report. Iran J Nucl Med. 2015;23(2):134–8.

    CAS  Google Scholar 

  17. Bal J, Goel G, Tiwari A, Chawla M, Dougall P, Chaturvedi H. Case report-primary hyperparathyroidism with brown tumors masquerading skeletal metastases–role of functional imaging in diagnosis and management. J Clin Transl Endocrinol: Case Rep. 2019;14:100054. https://doi.org/10.1016/j.jecr.2019.100054.

    Article  Google Scholar 

  18. Basaran Y, Ince S, Alagoz E, Meric C, Taslipinar A. An unusual presentation of primary hyperparathyroidism: multiple brown tumors and coexisting thyroid carcinoma. Rev Esp Med Nucl Imagen Mol. 2016;35(5):321–4. https://doi.org/10.1016/j.remn.2016.02.005.

    Article  CAS  PubMed  Google Scholar 

  19. Dias D, Pereira JS, Leite V. 99mTc sestamibi scintigraphy and primary hyperparathyroidism: uptake beyond parathyroid glands. BMJ Case Rep. 2018. https://doi.org/10.1136/bcr-2018-225232.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Hannaa RM, Hasnaina H, Sangalangb MD, Hanc J, Arasuc A, Arman F, et al. Three patients with lithium-associated hyperparathyroidism: literature review regarding medical and surgical management. Case Rep Nephrol Dial. 2019;9:108–18. https://doi.org/10.1159/000502399.

    Article  Google Scholar 

  21. Housseini YEl, Hübner M, Boubaker A, Bruegger J, Matter M. Unusual presentations of functionalparathyroid cysts: a case series and review of the literature. J Med Case Rep. 2017. https://doi.org/10.1186/s13256-017-1502-1.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Muñoz Garach A, Fernández García D, Molina Vega M, Sebastian-Ochoa A, Martinez del Valle Torres MD, Amrani-Raissouni T, et al (2014) Biochemical response and imaging changes in 99mTc-MIBI in patiens with primary hyperparathyroidism treated with cinacalcet. ECE 2014. Available in: https://www.endocrine-abstracts.org/ea/0035/ea0035p106. Accessed 1 May 2021.

  23. Nyakale N, Lockhat Z, Sathekge MM. Nuclear medicine-induced allergic reactions. Curr Allergy Clin Immunol. 2015;28(1):10–7.

    Google Scholar 

  24. Rocha Pinto S, Cavalcanti Santos LF, Rezende dos Reis SR, Keuper Bastos M, da Silva GV, de Oliveira Vieira T, et al. Adverse reactions to radiopharmaceuticals: a survey based on clinical cases using criteria of systematic review. Ther Innov Regul Sci. 2018;52(1):109–13. https://doi.org/10.1177/2168479017716717.

    Article  Google Scholar 

  25. Taieb D, Ureña-Torres P, Zanotti-Fregonara P, Rubello D, Ferretti A, Henter I, et al. Parathyroid scintigraphy in renal hyperparathyroidism. The added diagnostic value of SPECT and SPECT/CT. Clin Nucl Med. 2013;38(8):630–5. https://doi.org/10.1097/RLU.0b013e31829af5bf.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sebikali MJ, Warwick JM, Doruyter AG. Combined versus subtraction-only technique in parathyroid scintigraphy: effect on scan interpretation. Nucl Med Commun. 2020;41:883–7. https://doi.org/10.1097/MNM.0000000000001239.

    Article  PubMed  Google Scholar 

  27. Friedman K, Somervell H, Patel P, Melton GB, Garrett-Mayer E, Dackiw APB, et al. Effect of calcium channel blockers on the sensitivity of preoperative 99mTc-MIBI SPECT for hyperparathyroidism. Surgery. 2004;136(6):1199–204. https://doi.org/10.1016/j.surg.2004.06.047.

    Article  PubMed  Google Scholar 

  28. Smaxwil C, Aschoff P, Reischl G, Busch M, Wagner J, Altmeier J, et al. [18F]fluoro-ethylcholine-PET Plus 4D-CT (FEC-PET-CT): a break-through tool to localize the “negative” parathyroid adenoma one year follow up results involving 170 patients. J Clin Med. 2021;10:1648. https://doi.org/10.3390/jcm10081648.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Broos WAM, Wondergem M, Van Der Zant FM, Schaper NC, Knol RJJ. Dynamic 18F-fluorocholine PET/CT for parathyroid imaging in patients with primary hyperparathyroidism. Nucl Med Commun. 2020;41:776–82. https://doi.org/10.1097/MNM.0000000000001217.

    Article  CAS  PubMed  Google Scholar 

  30. Broos WAM, Wondergem M, Knol RJJ, Van Der Zant FM. Parathyroid imaging with 18F-fluorocholine PET/CT as a first-line imaging modality in primary hyperparathyroidism: a retrospective cohort study. EJNMMI Res. 2019;9:72. https://doi.org/10.1186/s13550-019-0544-3.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Broos WAM, Wondergem M, Knol RJJ, Van Der Zant FM, Knol RJJ. Dual-time-point 18F-fluorocholine PET/CT in parathyroid imaging. J Nucl Med. 2019;60:1605–10. https://doi.org/10.2967/jnumed.118.225599.

    Article  CAS  PubMed  Google Scholar 

  32. Roef MJ, van der Poel H, van der Laken CJ, Vogel WV. Colchicine must be stopped before imaging with [18F]-methylcholine PET/CT. Nucl Med Commun. 2010;31(12):1075–7. https://doi.org/10.1097/mnm.0b013e328340c5a0.

    Article  PubMed  Google Scholar 

  33. Treglia G, Piccardo A, Imperiale A, Strobel K, Kaufmann PA, Prior JO, et al. Diagnostic performance of choline PET for detection of hyperfunctioning parathyroid glands in hyperparathyroidism: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2019;46(3):751–65. https://doi.org/10.1007/s00259-018-4123-z.

    Article  CAS  PubMed  Google Scholar 

  34. Kim SJ, Lee SW, Jeong SY, Pak K, Kim K. Diagnostic performance of 18F-fluorocholine PET/CT for parathyroid localization in hyperparathyroidism: a systematic review and meta-analysis. Horm Cancer. 2018;9(6):440–7. https://doi.org/10.1007/s12672-018-0347-4.

    Article  CAS  PubMed  Google Scholar 

  35. Evangelista L, Ravelli I, Magnani F, Iacobone M, Giraudo C, Camozzi V, et al. 18F-choline PET/CT and PET/MRI in primary and recurrent hyperparathyroidism: a systematic review of the literature. Ann Nucl Med. 2020;34(9):601–19. https://doi.org/10.1007/s12149-020-01507-1.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Kluijfhout WP, Pasternak JD, Thurston Drake F, Beninato T, Gosnell JE, Shen WT, et al. Use of PET tracers for parathyroid localization: a systematic review and meta-analysis. Langenbecks Arch Surg. 2016;401:925–35. https://doi.org/10.1007/s00423-016-1425-0.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wong KK, Fig LM, Gross MD, Dwamena BA. Parathyroid adenoma localization with 99mTc-sestamibi SPECT/CT: a meta-analysis. Nucl Med Commun. 2015;36(4):363–75. https://doi.org/10.1097/MNM.0000000000000262.

    Article  CAS  PubMed  Google Scholar 

  38. Treglia G, Sadeghi R, Schalin-Jäntii C, Caldarella C, Ceriani L. Detection rate of 99mTc-MIBI SPECT/CT in the preoperative planning of patients with primary hyperparathyroidism: a meta-analysis. Head Neck. 2016;38(Suppl 1):E2159–72. https://doi.org/10.1002/hed.24027.

    Article  PubMed  Google Scholar 

  39. Tunninen V, Varjo P, Schildt J, Ahonen A, Kauppinen T, Lisinen I, et al. Comparison of five parathyroid scintigraphic protocols. Int J Mol Imaging. 2013;2013: 921260. https://doi.org/10.1155/2013/921260.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Broos WAM, van der Zant FM, Knol RJJ, Wondergem M. Choline PET/CT in parathyroid imaging: a systematic review. Nucl Med Commun. 2019;40(2):96–105. https://doi.org/10.1097/MNM.0000000000000952.

    Article  PubMed  Google Scholar 

  41. Giovanella L, Bacigalupo L, Treglia G, Piccardo A. Will 18F- fluorocholine PET/CT replace other methods of preoperative parathyroid imaging? Endocrine. 2021;71:285–97. https://doi.org/10.1007/s12020-020-02487-y.

    Article  CAS  PubMed  Google Scholar 

  42. Kołodziej M, Bober B, Saracyn M, Kamiński G. The role of PET/CT with 11C-methionine in contemporary nuclear medicine. Wiad Lek. 2020;73(9):2076–9. https://doi.org/10.36740/WLek202009234.

    Article  PubMed  Google Scholar 

  43. Botushanova AD, Botushanov NP, Yaneva MP. Nuclear medicine methods for evaluation of abnormal parathyroid glands in patients with primary and secondary hyperparathyroidism. Folia Med. 2017;59(4):396–404. https://doi.org/10.1515/folmed-2017-0054.

    Article  Google Scholar 

  44. Hindié E, Zanotti-Fregonara P, Tabarin A, Rubello D, Morelec I, Wagner T, et al. The role of radionuclide imaging in the surgical management of primary hyperparathyroidism. J Nucl Med. 2015;56:737–44. https://doi.org/10.2967/jnumed.115.156018.

    Article  PubMed  Google Scholar 

  45. Hafeez S, Saad M, Ilyas H, Smith A, Velusamy A, McGowan B, et al. Relationships between serum calcium and parathyroid hormone levels on effectiveness of parathyroid scintigraphy with Sestamibi. Endocr Abstr. 2019. https://doi.org/10.1530/endoabs.65.P81.

    Article  Google Scholar 

  46. Faqeeh J, Hassine H, Daghistani T, Nasr H, Farghaly H. Correlation between 99mTc- MIBI parathyroid scan findings and parathormon and calcium levels in patient with hyperparathyroidism. J Nucl Med. 2019;60(supplement 1):2017.

    Google Scholar 

  47. Kobylecka M, Koperski Ł, Chudziński W, Pihowicz P, Mączewska J, Płazińska MT, et al. Relationship between parathyroid gland scintigraphy and its histopathology, oxyphil cell content and volume: a retrospective study. Nucl Med Rev Cent East Eur. 2019;22(1):29–33. https://doi.org/10.5603/NMR.2019.0005.

    Article  PubMed  Google Scholar 

  48. Erovic BM, Goldstein DP, Asa SL, Janik S, Mete O, Irish JC. VEGFR-2 is downregulated in sestamibi-negative parathyroid adenomas. Head Neck. 2019;41(10):3564–9. https://doi.org/10.1002/hed.25871.

    Article  PubMed  Google Scholar 

  49. Paillahueque G, Massardo T, Barberán M, Ocares G, Gallegos I, Toro L, et al. Análisis de falsos negativos en la cintigrafía SPECT de paratiroides con sestamibi en pacientes con hiperparatiroidismo primario sometidos a cirugía entre 2008–2015 en hospital universitario. Rev Med Chile. 2017;145(8):1021–7. https://doi.org/10.4067/s0034-98872017000801021.

    Article  PubMed  Google Scholar 

Download references

Funding

This study did not receive financial support of any kind.

Author information

Authors and Affiliations

  1. Specialist in Nuclear Medicine and Epidemiology, Universidad Autónoma de Bucaramanga (UNAB)-Bogotá Surgery Society-San José Hospital, Bogotá, Colombia

    Marylin Acuña Hernandez

  2. Specialist in Nuclear Medicine, SPECT Medicina Nuclear S.A.S. Bucaramanga, Santander, Colombia

    Liset Sanchez Orduz

  3. Specialist in Nuclear Medicine, Highly Specialized in Nuclear Oncology and Nuclear Neurosciences, Instituo Mexicano del Seguro Social, Centro Medico Nacional Siglo XXI, Hospital de Pediatria, Ciudad de México, México

    Uvi Cancino Ramos

  4. Specialist in Nuclear Medicine-Highly Specialized in Nuclear Oncology, Ciudad de México, México

    Paola Vallejo Armenta

  5. Specialist in Nuclear Medicine-Head of the Nuclear Medicine Service, Bogotá Surgery Society-San José Hospital-Fundación de Ciencias Universitarias de la Salud (FUCS), Bogotá, Colombia

    Leonardo Cadavid Blanco

Authors
  1. Marylin Acuña Hernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Liset Sanchez Orduz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Uvi Cancino Ramos
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Paola Vallejo Armenta
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leonardo Cadavid Blanco
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the different processes of the formation of this manuscript.

Corresponding author

Correspondence to Marylin Acuña Hernandez.

Ethics declarations

Conflict of interest

All authors declare that they have no conflicts of interest.

Ethical approval

As it is a review article, there was no experimentation on animals or persons, and so informed consent or approval from the ethics committee was not required.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Acuña Hernandez, M., Sanchez Orduz, L., Cancino Ramos, U. et al. Is there a consensus between clinical practice guidelines for conventional and molecular nuclear medicine studies in parathyroid pathology?. Ann Nucl Med 35, 994–1003 (2021). https://doi.org/10.1007/s12149-021-01658-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-021-01658-9

Keywords

Search

Navigation